Sign in Subscribe
Biochemistry

Biomarkers for Traumatic Brain Injury Show Promise but Require Standardization

Strategic Insights

— 2 min read

Researchers at Jackson Memorial Hospital have conducted a new study on the predictive value of biomarkers for traumatic brain injury (TBI). The study, published in the journal Neurology, explored the relative effectiveness of four biomarkers (S100 calcium-binding protein B, glial fibrillary acidic protein, neuron-specific enolase, and ubiquitin carboxy-terminal hydrolase L1) in predicting mortality and functional outcomes after moderate-to-severe TBI. The research found that all four biomarkers showed statistically significant effects in predicting mortality, with sensitivity ranging from 57% to 94%. However, for functional outcomes, the results were less clear-cut, with only S100B and GFAP showing significant effects.

Key Takeaways:

  • The study included 32 studies with a total of 2,401 participants, focusing on moderate-to-severe TBI.
  • The researchers found significant effects for all four biomarkers in predicting mortality, with sensitivity ranging from 57% to 94%.
  • S100B had a standardized mean difference (SMD) of 0.80 (0.58-1.01) and sensitivity of 62% in predicting functional outcomes.
  • GFAP showed a higher SMD of 1.03 (0.65-1.41) and sensitivity of 89% in predicting functional outcomes.
  • The study concluded that further research is needed to standardize protocols for measuring/providing data on biomarkers and to integrate them into predictive models for clinical use.
  • The research was conducted by a team of researchers from Jackson Memorial Hospital, including Fernanda Jacinto Pereira Teixeira, Lilian Maria Godeiro Coelho, and others.

Statistics:

  • 1,680 studies were searched, with 32 included in the final analysis.
  • 2,401 participants were involved in the study.
  • The biomarkers showed the following statistical effects in predicting mortality:

+ S100B: SMD = 1.35 [0.99-1.71], sensitivity = 83%.

+ GFAP: SMD = 2.25 [1.40-3.11], sensitivity = 94%.

+ NSE: SMD = 0.71 [0.12-1.29], sensitivity = 88%.

+ UCH-L1: mean difference [MD] = 1.06 [0.72-1.40], sensitivity = 57%.

  • The biomarkers showed the following statistical effects in predicting functional outcomes:

+ S100B: SMD = 0.80 [0.58-1.01], sensitivity = 62%.

+ GFAP: SMD = 1.03 [0.65-1.41], sensitivity = 89%.

+ NSE: SMD = 0.73 [0.52-0.94], sensitivity = 41%.

+ UCH-L1: MD = 0.86 [0.72-1.00], sensitivity = 0%.

Sources:

  • NewsRx. Researchers at Jackson Memorial Hospital Target Traumatic Brain Injury (Predictive Value of Nervous Cell Injury Biomarkers in Moderate-to-Severe Traumatic Brain Injury: A Network Meta-Analysis). Health & Medicine Week. September 19, 2025; p 5703.
  • Predictive Value of Nervous Cell Injury Biomarkers in Moderate-to-Severe Traumatic Brain Injury: A Network Meta-Analysis. Neurology, 2025;105(5).

Read more